Other Agreements - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Other Agreements [Line Items]
Upfront consideration paid in exchange of common stock		5,587
Asset purchase agreement fixed payments paid for first two years		$ 740,000
Percentage on annual revenues for cash consideration to be paid		6.00%
Asset purchase agreement aggregate cash compensation paid		$ 15,000,000
Deferred payment obligation interest percentage		5.00%
Discount rate used to calculate asset purchase obligation		2.50%
Debt instrument, amortization expense		$ 206,985	$ 281,013
Research and development		$ 7,900,311	4,601,718
Agreement expiration date		Oct. 31, 2019
Description on termination of agreement		The Company may terminate the agreement at any time upon 90 days’ written notice and may terminate any development plan under the agreement upon 30 days’ prior written notice. Illumina may terminate the agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control. Either party may terminate the agreement upon the other party’s material breach of the agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.
Service Revenue		$ 2,372,788	183,758
Recognition of deferred revenue		160,106	0
Revenue recognized		5,132,730	4,041,575
Collaborative Arrangement
Other Agreements [Line Items]
Service Revenue		$ 189,442
LTC
Other Agreements [Line Items]
Agreement commencement period		2016-03
Non-cancellable purchase order value				$ 250,000
Agreement expiration date		2021-03
Automatic renewal term of agreement		2 years
Agreement termination notice period		60 days
Number of days material breach remains uncured		30 days
Bristol-Myers Squibb
Other Agreements [Line Items]
Agreement expiration date		May 11, 2019
Agreement termination notice period		90 days
Number of days material breach remains uncured		60 days
Merck KGaA Agreement
Other Agreements [Line Items]
Description on termination of agreement		Merck KGaA may terminate the Project by providing 90 days’ prior written notice to the Company, at which point Merck KGaA will reimburse HTG for costs incurred during the termination period, of an amount not to exceed non-cancellable, non-reimbursable expenses, and HTG will reimburse Merck KGaA for any costs that have been prepaid without being incurred prior to termination. Further, either party may also terminate the agreement upon the other party’s material breach that remains uncured for 45 days or upon the other party’s bankruptcy.
Agreement commencement period		2016-10
Agreement termination notice period		90 days
Number of days material breach remains uncured		45 days
Up-front and milestone payments receivable		$ 9,900,000
Up-front and milestone payments receivable period		9 years
Up-front payments received		$ 0
Revenue recognized		0
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones		1,000,000
Research and development	$ 100,000
Invetech PTY Ltd. Agreement
Other Agreements [Line Items]
Research and development		2,300,000	300,000
Growth Term Loan
Other Agreements [Line Items]
Minimum payments of pledged intangible assets due in 2014		868,750
Minimum payments of pledged intangible assets due in 2015		868,750
Minimum payments of pledged intangible assets due in first quarter of 2016		868,750
Minimum payments of pledged intangible assets due in second quarter of 2016		543,750
Debt instrument, amortization expense		249,868	170,954
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due in current year		543,750
Asset purchase agreement quarterly installments due in 2017		800,000
Accrued revenue-based payments		0
NuvoGen
Other Agreements [Line Items]
Convertible notes and related debt discount	$ 283,621	76,636	283,621
Debt instrument, amortization expense		206,985	$ 281,013
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018		400,000
Maximum | Merck KGaA Agreement
Other Agreements [Line Items]
Up-front and milestone payments receivable		$ 1,850,000
Up-front and milestone payments receivable period		5 years